Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jan 21, 2021; 27(3): 267-280
Published online Jan 21, 2021. doi: 10.3748/wjg.v27.i3.267
Table 1 Demographics and primary tumor characteristics for cohort with anorectal melanoma (n = 24)
Classification

n
Age, years (median, IQR)65.5 (54-76)
≤ 503 (12.5)
51–607 (29.2)
61–706 (25.0)
71–806 (25.0)
> 802 (8.3)
SexM8 (33.3)
F16 (66.7)
RaceWhite23 (95.8)
Latino1 (4.2)
RuralYes5 (20.8)
No19 (79.2)
Breslow depth (mm)≤ 56 (25.0)
> 57 (29.2)
Unknown11 (45.8)
UlcerationPresent9 (37.5)
Absent2 (8.3)
Unknown13 (54.2)
Mitoses> 17 (29.2)
Unknown17 (70.8)
StageI12 (50.0)
II8 (33.3)
III4 (16.7)
Table 2 Treatment details for cohort with anorectal melanoma (n = 24)

Treatment

Primary operation, nWE15 (62.5)
APR2 (8.3)
Biopsy alone7 (29.2)
Primary nodal operation, nSLNB6 (25.0)
CLND3 (12.5)
None15 (62.5)
Adjuvant therapy, n1Chemotherapy alone0 (0)
Radiation alone1 (4.2)
Interferon alone3 (12.5)
Checkpoint Inhibitor3 (12.5)
Combination chemotherapy/radiation2 (8.3)
Combination chemotherapy/immunotherapy3 (12.5)
Combination radiation/immunotherapy1 (4.2)
None11 (45.8)
Surgery at recurrence2APR1 (9.1)
WE1 (9.1)
Non-operative therapies at recurrence2Chemotherapy 1 (9.1)
Radiation 0 (0)
Interferon0 (0)
Checkpoint Inhibitor2 (18.2)
Combination chemotherapy/radiation4 (26.7)
Combination chemotherapy/immunotherapy2 (13.3)
Combination radiation/immunotherapy2 (13.3)
Table 3 Studies included in literature review and select outcomes
Ref.
Date published
Location
Dates included
Sample size
Median age
M/F (n)
APR/WE (n)
Median OS
APR vs WE (% survival to 5 yr)
Overall 5 yr survival (%)
Pack et al[40]1967Pack Medical Foundation, United States1930-19652053.515/1511/3--5
Abbas et al[41]1980Roswell Park Memorial Institute, United States1930-19792061.74/1611/718.8120.1 mo vs 8.5 mo37
Ward et al[42]1986St. Mark's Hospital, United Kingdom1932-198221-12/99/68.81-0
Thibault et al[21]1996Mayo Clinic, United States1939-19935063115/3526/10261,218 vs 1922
Wanebo et al[25]1990Memorial Sloan Kettering Cancer Center, United States1950-1977366015/2122/81416/7 mo vs 21.5 mo3,48
Ross et al[27]1990MD Anderson Cancer Center, United States1952-198832--14/1218.619.5 mo vs 18.9 mo33
Dodds et al[43]2019Melanoma Institute Australia, Australia1958-2016436121/2220/1524-16
Siegal et al[44]1983Sheba Medical Center, Israel1960-19813064113/1715/910.51-7
Roumen et al[45]1996Eindhoven Cancer Registry, Netherlands1960-1995636627/3621/18--6
Nilsson et al[46]2010Swedish National Cancer Registry, Sweden1960-199925173101/15066/8611.27 vs 15, P = 0.08
Podnos et al[47]2006City of Hope National Medical Center, United States1973-200112669.2139/87-15-19
Slingluff et al[48]1990Duke University Medical Center, United States1974-1988246417/1713/81818 vs 128
Belli et al[49]2008National Institute of Cancer, Italy1975-2006406319/2113/181718.5 vs 18.5, P = 0.97-
Che et al[22]2011Peking Union Medical College, China1975-200856-22/3436/202124.6 vs 9.9, P = 0.6520
Pessaux et al[50]2004Institut Gustave Roussy, France1977-20023058.17/239/211716 vs 3317
Ramakrishnan et al[51]2008Cancer Institue (WIA), India1980-200463-34/293/89.52-5
Yeh et al[26]2006Memorial Sloan Kettering Cancer Center, United States1984-2003465918/2819/2739532 vs 35, P = 0.665-
Homsi et al[52]2007H. Lee Moffitt Cancer Center, United States1987-200412673/95/6---
Bullard et al[53]2003University of Minnesota, United States1988-2002156516/94/1118614 mo vs 19 mo3-
Kelly et al[10]2010MD Anderson Cancer Center, United States1989-2008546119/350/5429-30
Das et al[19]2003Tata Memorial Hospital, India1990-20017249120/5224/0132,5-82
Hicks et al[28]2014John Hopkins Hospital, United States1991-2012186410/87/1115.511.5 mo vs 13.5 mo, P = 0.753-
Yen et al[54]2013Chang Gung Memorial Hospital, China1993-20112258.418/1412/8-0 vs 28.6, P = 0.069
Zhang et al[7]2010First Affiliated Hospital of Guangxi Medical University, China1995-2007545421/3339/152530 vs 16, P = 0.2826
Aytac et al[55]2010Uludag University, Turkey1997-200414588/611/37.5-0
Ishizone et al[32]2008Shinshu University Hospital, Japan1997-20067965.8134/4563/1422-29
Belbaraka et al[56]2012National Institute of Oncology, Morocco1998-20071758112/57/38--
Choi et al[9]2010Samsung Medical Center, South Korea1999-200819618/1112/745.950 vs 032
Miguel et al[23]2015IPOFG, Portugal2000-20111070.52/85/19.3-20
Ranjith et al[20]2018Regional Cancer Center Thiruvanathapuram, India2001-2013315612/199/09-0
Ren et al[24]2018Fudan University Shanghai Cancer Center, China2005-2017606118/4238/22--33.35
Nusrath et al[57]2018Basavatakrakam Indo American Cancer Hospital, India2010-2015305015/1515/51313 vs 36, P = 0.48-
Sahu et al[58]2017Tata Memorial Hospital, India2013-2015375425/12-7--